Benitec On Track to Begin HCV Trial in '13 as It Works to Raise Investor Interest | GenomeWeb

With an investigational new drug application ready for submission to US regulators, Australian firm Benitec Biopharma anticipates launching a phase I/IIa study of its hepatitis C treatment TT-034 before the end of the year, the company's chief executive said this week.

Meanwhile, Benitec is also laying the groundwork for a follow-on phase IIb trial of the drug and preparing for the possibility that it will run the trial on its own by drumming up interest in the company among those in the investment community, CEO Peter French told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."